CN116549534B - Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions - Google Patents
Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions Download PDFInfo
- Publication number
- CN116549534B CN116549534B CN202310713063.0A CN202310713063A CN116549534B CN 116549534 B CN116549534 B CN 116549534B CN 202310713063 A CN202310713063 A CN 202310713063A CN 116549534 B CN116549534 B CN 116549534B
- Authority
- CN
- China
- Prior art keywords
- chicks
- intestinal
- mannooligosaccharide
- growth
- egg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 230000003871 intestinal function Effects 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 37
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 37
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 37
- 240000002624 Mespilus germanica Species 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 27
- 241000287828 Gallus gallus Species 0.000 claims description 24
- 235000013330 chicken meat Nutrition 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 11
- 210000004534 cecum Anatomy 0.000 abstract description 10
- 210000000813 small intestine Anatomy 0.000 abstract description 9
- 108020004999 messenger RNA Proteins 0.000 abstract description 8
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 abstract description 7
- 241000186660 Lactobacillus Species 0.000 abstract description 7
- 102000003940 Occludin Human genes 0.000 abstract description 7
- 108090000304 Occludin Proteins 0.000 abstract description 7
- 229940039696 lactobacillus Drugs 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 5
- 230000006862 enzymatic digestion Effects 0.000 abstract description 4
- 230000007358 intestinal barrier function Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 230000008384 membrane barrier Effects 0.000 abstract description 2
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 102000011154 Tight junction protein ZO-1 Human genes 0.000 abstract 1
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 description 42
- 230000000694 effects Effects 0.000 description 34
- 244000182216 Mimusops elengi Species 0.000 description 31
- 244000241838 Lycium barbarum Species 0.000 description 28
- 235000015459 Lycium barbarum Nutrition 0.000 description 28
- 238000012360 testing method Methods 0.000 description 12
- 235000015468 Lycium chinense Nutrition 0.000 description 10
- 230000002183 duodenal effect Effects 0.000 description 9
- 210000001630 jejunum Anatomy 0.000 description 7
- 210000003405 ileum Anatomy 0.000 description 6
- 102100034263 Mucin-2 Human genes 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for promoting the growth of egg chicks and regulating intestinal functions, which consists of 1 g-2 g/kg of medlar and 0.4g/kg of mannooligosaccharide. The composition selects the optimal combination proportion according to physiological characteristics of different growth stages of the egg chicks, promotes the growth of the chicks, and improves intestinal digestion function and mucous membrane barrier function of the chicks. In vivo experiments show that: the combination of the two can enhance the growth performance of the egg chicks, enhance the digestion function of the chicks by enhancing the intestinal digestive enzyme activity, enhance the villus height and the villus cryptoratio of the small intestine, enhance the intestinal barrier function by up-regulating the relative expression quantity of intestinal tissue tight junction protein ZO-1, mucin MUC2 and atresia Occludin mRNA, and regulate the intestinal health state by reducing the pH of the cecum and increasing the number of lactobacillus in the cecum content.
Description
Technical Field
The invention relates to the technical field of Chinese herbal medicines and the technical field of poultry anti-pathogen cultivation, in particular to a pharmaceutical composition for promoting the growth of egg chickens and regulating intestinal functions.
Background
Due to excessive and excessive use of antibiotics, bacterial drug resistance is generated, the clinical treatment effect of veterinary antibiotics is reduced, the dosage of antibiotics is forced to be increased in the breeding industry, the residual risk of veterinary antibacterial drugs is increased, and the quality safety of livestock and poultry products is threatened.
The wolfberry fruits are rich in rich alkaloid, polysaccharide, flavonoid, fenic acid and other components, have the effects of resisting inflammation, regulating immunity, promoting growth, enhancing intestinal barrier and the like, and according to statistics, the annual planting area of the wolfberry fruits in Ningxia county exceeds 20 mu, the annual yield of dried wolfberry fruits exceeds 40000 tons, and the leftovers (mainly inferior fruits: too small fruits, broken fruits and pomace) generated in the wolfberry processing process reach over 2000 tons.
The mannooligosaccharide has been widely studied in human and animal health care, and has the effects of promoting growth, improving immunity and regulating the environment in intestinal tract, and has the advantages of less drug resistance and less drug residue.
However, the effect of single use of traditional Chinese medicine or mannooligosaccharide may have a certain limitation, so that a high-efficiency combination scheme is sought, and therefore, the screening of effective medicines in traditional Chinese herbal medicines and the combination of mannooligosaccharide are used for replacing growth-promoting antibiotics, thereby completely meeting the development requirements of healthy cultivation in modern society.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide a pharmaceutical composition for promoting the growth of the egg chicks and regulating the intestinal functions, and the pharmaceutical composition combines medlar fruit powder and mannooligosaccharide, so that the growth performance of the egg chicks is effectively improved, and the intestinal functions are enhanced.
The technical scheme adopted for achieving the aim of the invention is as follows: a pharmaceutical composition for promoting the growth of egg chicks and regulating intestinal functions comprises 1 g-2 g/kg of medlar and 0.4g/kg of mannooligosaccharide.
The optimal proportion of the pharmaceutical composition for promoting the growth of the egg chicks and regulating the intestinal functions is composed of 2g/kg of medlar and 0.4g/kg of mannooligosaccharide.
The invention relates to a pharmaceutical composition for promoting the growth of egg chickens and regulating intestinal functions, wherein medlar is medlar powder.
The invention relates to a pharmaceutical composition for promoting the growth of egg chickens and regulating intestinal functions, wherein the egg chickens are 7-49 days old.
It is still another object of the present invention to provide a pharmaceutical composition for promoting the growth of egg chickens and regulating intestinal function for the treatment of intestinal digestive function and intestinal mucosal barrier function.
The specific application of the pharmaceutical composition for promoting the growth of the egg chicks and regulating the intestinal functions in different growth stages of the egg chicks is as follows:
s1, in the daily ration of the chicks 7, starting to use 2g/kg, 1g/kg and 0.5g/kg of medlar residual fruit powder and above doses respectively with 0.4g/kg of mannooligosaccharide and 0.4g/kg of mannooligosaccharide in the daily ration, and calculating the average daily gain and the feed-weight ratio of the chicks per week.
S2, under the same treatment as the S1, determining the duodenal digestive enzyme activity of the chicks at 28 days old and 49 days old respectively, and determining the villus height, the crypt depth and the villus-crypt ratio of the small intestine, thereby determining the relative expression quantity of the protein mRNA related to the mucous membrane barrier of the small intestine.
According to the application method, the chicks are divided into different growth stages according to daily ration, and proper combination proportion is selected according to physiological characteristics of each growth stage and the existing research results, so that the medication science and safety are improved, and meanwhile, the production investment is reduced.
Drawings
FIG. 1 is a graph showing the effect of adding 2g/kg of wolfberry to the diet on the activity of the duodenal digestive enzyme of a chick;
FIG. 2 is a graph showing the effect of the combination of 2g/kg of wolfberry and 0.4g/kg of mannooligosaccharide on the activity of the duodenal digestive enzyme of a chick;
FIG. 3 is a graph showing the effect of adding 1g/kg of wolfberry and 0.4g/kg of mannooligosaccharide to the chick duodenal digestive enzyme activity;
FIG. 4 is a graph showing the effect of high doses of Lycium barbarum and mannooligosaccharide on the relative expression levels of chicken intestine Occlude;
FIG. 5 is a graph showing the effect of high doses of Lycium barbarum and mannooligosaccharide on the relative expression level of ZO-1mRNA in the small intestine of chickens;
FIG. 6 is a graph showing the effect of the dose of Lycium barbarum and mannooligosaccharide on the relative expression level of chicken intestine Occlude;
FIG. 7 is a graph showing the effect of the dose of Lycium barbarum and mannooligosaccharide on the relative expression level of ZO-1mRNA in the small intestine of chicks;
FIG. 8 is a graph showing the effect of low dose matrimony vine and mannooligosaccharide on the relative expression level of chick small intestine Occludin;
FIG. 9 is a graph showing the effect of low dose of Lycium barbarum and mannooligosaccharide on the relative expression level of ZO-1mRNA in the small intestine of chicks;
FIG. 10 is a graph showing the effect of high doses of Lycium barbarum and mannooligosaccharide on the relative expression level of MUC2 mRNA in the intestinal tract of chickens;
FIG. 11 is a graph showing the effect of dose of matrimony vine and mannooligosaccharide on the relative expression level of MUC2 mRNA in the intestinal tract of chickens;
FIG. 12 is a graph showing the effect of low doses of matrimony vine and mannooligosaccharide on the relative expression level of MUC2 mRNA in the intestinal tract of chickens;
FIG. 13 is a graph showing the effect of matrimony vine and mannooligosaccharide on the number of E.coli in chickens;
FIG. 14 is a graph showing the effect of matrimony vine and mannooligosaccharide on the number of Lactobacillus cecum in chickens.
Detailed Description
Hereinafter, only certain exemplary embodiments are briefly described. As will be recognized by those skilled in the pertinent art, the described embodiments may be modified in numerous different ways without departing from the spirit or scope of the embodiments of the present invention, which should also be considered as being within the scope of the present invention. Accordingly, the description of the embodiments is to be regarded as illustrative in nature and not as restrictive.
Example 1
A pharmaceutical composition for promoting growth of egg chicken and regulating intestinal function comprises 1g/kg fructus Lycii and 0.4g/kg mannooligosaccharide.
Example 2
A pharmaceutical composition for promoting growth of egg chicken and regulating intestinal function comprises fructus Lycii 2g/kg and mannooligosaccharide 0.4 g/kg.
Test example 1: testing of growth performance of egg chicks
Chicks are randomly divided into 8 groups, 3 level repeats are set, each repeat is carried out on 12 chicks, 2g/kg, 1g/kg, 0.5g/kg of medlar residue fruit powder and above in daily ration are respectively combined with 0.4g/kg of mannooligosaccharide and 0.4g/kg of mannooligosaccharide in daily ration 7 daily ration, and specific groups are shown in table 1. The test period was 42 days. In the raising process, the raising conditions of each group of chicks are consistent, the chicks can eat and drink water freely, and the chicken house can be subjected to normal disinfection and immunization procedures.
TABLE 1 chick grouping
| Grouping | Treatment of |
| Blank group (CON) | Basic daily ration for feeding |
| High-dose group of defective medlar fruit (LBH) | Basic ration +2g/kg of medlar residual fruit |
| Chinese wolfberry incomplete fruit dose group (LBM) | Basic ration +1g/kg of medlar residual fruit |
| Chinese wolfberry fruit low dose group (LBL) | Basic ration plus 0.5g/kg of medlar residual fruit |
| High dose combination (LBH+ACT) | Basic ration, 2g/kg of medlar residual fruit and 0.4g/kg of mannooligosaccharide |
| Medium dose combination (LBM+ACT) | Basic ration, 1g/kg of medlar residual fruit and 0.4g/kg of mannooligosaccharide |
| Low dose combination (LBL+ACT) | Basic ration, 0.5g/kg of medlar residual fruit, 0.4g/kg of mannooligosaccharide |
| Mannooligosaccharide group (ACT) | Basic ration plus 0.4g/kg mannooligosaccharide |
Note that: the control group, the high, medium, low dose combination group, and the mannooligosaccharide group are denoted by CON, LBH, LBM, LNL, LBH +act, lbm+act, lbl+act, and ACT, respectively, and are the same in the following tables and figures.
The weekly feed consumption of the test chicks was recorded during the test, the weight was weighed on an empty stomach before feeding every morning and recorded, and the Average Daily Gain (ADG) and the feed-to-weight ratio (F/G) of the chicks per week were calculated.
As shown in Table 2, when 2g/kg of fructus Lycii residue fruit powder and 0.4g/kg of mannooligosaccharide are mixed for feeding, average daily weight gain of chicks at 3, 4, 6 and 7 weeks can be improved, and the feed-weight ratio of 6 and 7 weeks can be reduced. Showing that the chick growth performance can be improved when 2g/kg of medlar residual fruit powder and 0.4g/kg of mannooligosaccharide are mixed for feeding.
TABLE 2 Effect of Lycium barbarum and mannooligosaccharide on chick growth Performance
Note that: the same lower case letters of the shoulder marks are compared with each other, two upper case letters indicate that the difference is extremely remarkable (P < 0.01), and one upper case letter indicates that the difference is remarkable (P < 0.05).
Test example 2: intestinal digestion function determination test for egg chicks
The above test example 1 group feeding scheme was carried out by dissecting chicks at 28 and 49 days of age, respectively, taking the duodenal contents, carrying out trypsin, lipase and amylase activity detection by using an enzyme activity test kit, taking the duodenum, jejunum and ileum sections, washing cleanly, placing in 4% paraformaldehyde, fully fixing to prepare paraffin sections, then HE staining, measuring the villus height and crypt depth of the small intestine, and calculating the villus-crypt ratio.
Fig. 1 to 3 are graphs showing the effect of various proportions of wolfberry and mannooligosaccharides on the activity of the chicken duodenal digestive enzyme. And (3) injection: * Indicating significant differences (P < 0.05), indicating very significant differences (P < 0.01).
As shown in figures 1-3, 2g/kg of medlar residual fruit powder and 2g/kg and 1g/kg of medlar residual fruit powder are added into daily ration, and when combined with 0.4g/kg of mannooligosaccharide, trypsin and lipase activities of 28-day old chickens and 49-day old chickens can be obviously improved; the combination of the three components can obviously improve the activity of 28-day-old duodenal amylase of chicks, and the combination effect of 2g/kg of medlar residual fruit powder and 0.4g/kg of mannooligosaccharide is the best.
2G/kg of medlar residual fruit powder and 2g/kg of medlar residual fruit powder are added into daily ration, and are respectively combined with 0.4g/kg of mannooligosaccharide, so that the jejunum villus height of 28-day-old chicks can be obviously increased; 1g/kg of medlar residual fruit powder is added, and the combination of the medlar residual fruit powder and 0.4g/kg of mannooligosaccharide can obviously improve jejunum villus height of 49-day-old chicks; the combination of 2g/kg and 1g/kg of medlar residual fruit powder and 0.4g/kg of mannooligosaccharide can obviously improve the villus height and the villus-to-crypto ratio of 28-day-old and 49-day-old ileum of chicks, as shown in tables 3, 4 and 5.
TABLE 3 influence of defective Lycium barbarum and mannooligosaccharide on the morphological structure of the duodenum of chicks
Note that: the same lower case letters of the shoulder marks are compared with each other, two upper case letters indicate that the difference is extremely remarkable (P < 0.01), and one upper case letter indicates that the difference is remarkable (P < 0.05).
TABLE 4 Effect of Lycium barbarum and mannooligosaccharide on the morphology and Structure of the jejunum of chicks
Note that: the same lower case letters of the shoulder marks are compared with each other, two upper case letters indicate that the difference is extremely remarkable (P < 0.01), and one upper case letter indicates that the difference is remarkable (P < 0.05).
TABLE 5 Effect of Lycium barbarum and mannooligosaccharide on ileum morphology in chicks
Note that: the same lower case letters of the shoulder marks are compared with each other, two upper case letters indicate that the difference is extremely remarkable (P < 0.01), and one upper case letter indicates that the difference is remarkable (P < 0.05).
It is proved that when 2g/kg and 1g/kg of medlar residual fruit powder and 0.4g/kg of medlar residual fruit powder are added into daily ration, the growth performance of chicks can be improved and the intestinal digestion function can be enhanced.
Test example 3: determination of chick intestinal mucosa barrier function
The above example 1 group feeding protocol was used to collect the duodenum, jejunum, and ileum of chicks at 28 and 49 days of age, respectively, and determine their relative amounts of barrier-related Occlutin, ZO-1, and MUC2 mRNA.
FIGS. 4 to 9 are graphs showing the effect of matrimony vine and mannooligosaccharide on the relative expression amounts of chicken small intestine Occludin and ZO-1mRNA, notes: * Indicating significant differences (P < 0.05), indicating very significant differences (P < 0.01).
Fig. 10 to 12 effect of matrimony vine and mannooligosaccharide on relative expression amount of chick intestinal MUC2 mRNA, note: * Indicating significant differences (P < 0.05), indicating very significant differences (P < 0.01).
From FIGS. 4 to 12, it is known that the combination of 2g/kg of the fructus Lycii residue fruit powder and 0.4g/kg of the mannooligosaccharide can increase the relative expression levels of jejunum Occludin and ZO-1mRNA of chicks at 28 days old, up-regulate the relative expression levels of intestinal Occludin and MUC2mRNA, up-regulate the relative expression levels of ileum Occludin at 49 days old, ZO-1 and MUC2mRNA and the relative expression level of MUC2mRNA of duodenum; the combination of 1g/kg of the medlar residual fruit powder and 0.4g/kg of the mannooligosaccharide can improve the relative expression quantity of the duodenal ZO-1 and jejunum MUC2mRNA of the chicks at 28 days old, and the combination of 0.5g/kg of the medlar residual fruit powder and 0.4g/kg of the mannooligosaccharide can improve the relative expression quantity of the duodenal ZO-1 and ileum ZO-1mRNA of the chicks at 49 days old.
Test example 4: determination of the pH of the cecal content and the intestinal flora of the chicks
The above example 1 group feeding protocol was used to collect cecum from chicks at 28 and 49 days of age, respectively, and the pH of the intestinal contents was measured with a pH meter, and the numbers of escherichia coli and lactobacillus were counted by plate counting.
The results are shown in Table 6, and it is clear that the combination of three doses of fructus Lycii residual fruit and 0.4g/kg of mannooligosaccharide can reduce the pH of 7-49 day-old cecum content of chicks, and the combination of 2g/kg of fructus Lycii residual fruit powder and 0.4g/kg of mannooligosaccharide has the best effect. TABLE 6 influence of defective Lycium barbarum and mannooligosaccharide on the pH of the cecum contents of chickens
| Grouping | 28 Days old | 49 Days old | |
| CON | 6.77±0.09a | 7.22±0.04a | |
| LBH | 6.45±0.05e | 7.17±0.01AAb | |
| LBM | 6.55±0.12b | 7.15±0.02AAb | |
| LBL | 6.77±0.08b | 7.20±0.01b | |
| LBH+ACT | 6.25±0.06AABBD | 7.02±0.03AABBDEE | |
| LBM+ACT | 6.22±0.06AABBE | 7.06±0.03AABB | |
| LBL+ACT | 6.21±0.04AABBE | 7.07±0.03AABBd | |
| ACT | 6.47±0.37AA | 7.09±0.02AAe |
Note that: the same lower case letters of the shoulder marks are compared with each other, two uppercase letters are extremely obvious in difference (P < 0.01), and one uppercase letter is obvious in difference (P < 0.05).
Fig. 13 to 14 are graphs showing the effects of the defective fruits of matrimony vine and mannooligosaccharides on the numbers of E.coli and Lactobacillus in chickens. And (3) injection: * Indicating significant differences (P < 0.05), indicating very significant differences (P < 0.01).
From FIGS. 13 to 14, it is understood that the combination of 2g/kg and 1g/kg of residual fruit powder of Lycium barbarum with 0.4g/kg of mannooligosaccharide can increase the number of Lactobacillus cecum in 28-day-old chicks; the daily ration is added with the residual fruit powder of the medlar and the combination of the residual fruit powder and 0.4g/kg of mannooligosaccharide, so that the quantity of lactobacillus in the cecum content of the 49-day-old chicks can be increased, and the combination effect of 2g/kg and 0.4g/kg of mannooligosaccharide is the best.
In the whole, when 2g/kg and 1g/kg of medlar residual fruit powder are added into daily ration and are respectively combined with 0.4g/kg of mannooligosaccharide, the intestinal mucosa barrier of the chick can be enhanced.
As can be seen from a combination of the above examples: when 2g/kg of medlar residue fruit powder and 0.4g/kg of mannooligosaccharide are added into daily ration of the egg chicks for combined use, the growth performance of the chicks can be improved by improving average daily gain of the chicks and reducing the feed-weight ratio; the intestinal tract digestive enzyme activity is improved, so that the small intestinal villus height and the villus cryptoratio are improved, and the digestion function of the chicks is enhanced; the intestinal barrier function is enhanced by up-regulating the relative expression levels of intestinal tissue-tight junction protein ZO-1, mucin MUC2, and atresia Occludin mRNA, and the intestinal health is regulated by lowering the cecum pH and increasing the number of Lactobacillus in the cecum contents.
Large group test: based on the above examples, the most suitable combination amount of 2g/kg of medlar residual fruit powder and 0.4g/kg of mannooligosaccharide are selected for feeding. Starting feeding at 7 days old, feeding for 10 days every month, and comparing egg yield and egg quality (eggshell color, eggshell strength, egg shape index, yolk color, etc.) of the laying hens before and after feeding.
Claims (4)
1. A pharmaceutical composition for promoting the growth of egg chicks and regulating intestinal functions, which is characterized in that: the composition consists of medlar and mannooligosaccharide, and the dosage of the medlar and the mannooligosaccharide is 1-2: 0.4.
2. A pharmaceutical composition for promoting the growth of egg chicks and regulating intestinal function according to claim 1, wherein: the composition consists of 2g medlar and 0.4 g mannooligosaccharide.
3. A pharmaceutical composition for promoting the growth of egg chickens and regulating intestinal function according to claim 1 or 2, wherein: the medlar is medlar powder.
4. Use of the pharmaceutical composition of claim 1 for the manufacture of a medicament for promoting growth of an egg chicken and regulating intestinal function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310713063.0A CN116549534B (en) | 2023-06-16 | 2023-06-16 | Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310713063.0A CN116549534B (en) | 2023-06-16 | 2023-06-16 | Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116549534A CN116549534A (en) | 2023-08-08 |
| CN116549534B true CN116549534B (en) | 2024-04-19 |
Family
ID=87486239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310713063.0A Active CN116549534B (en) | 2023-06-16 | 2023-06-16 | Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116549534B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102987107A (en) * | 2012-09-29 | 2013-03-27 | 凤台县瑞普农业发展有限公司 | Chick feed |
-
2023
- 2023-06-16 CN CN202310713063.0A patent/CN116549534B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102987107A (en) * | 2012-09-29 | 2013-03-27 | 凤台县瑞普农业发展有限公司 | Chick feed |
Non-Patent Citations (2)
| Title |
|---|
| Effects of mannan-oligosaccharide supplementation on gut health, immunity, and production performance of broilers.;Asif M;Brazilian journal of biology;20220101;第84卷;e250132-e250132 * |
| Goloba kusi (Hornstedtia scottiana [F. Muell.] K. Schum.) fruit as a feed additive to improve the histological structures and growth performance of broiler;Blatama D等人;Veterinary world;20230228;第16卷(第2期);329-340 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116549534A (en) | 2023-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101554206B (en) | Composite plant feed additive | |
| CN102894210B (en) | Anti-stress Chinese herbal medicine composite feedstuff additive specially used for penaeus vannamei | |
| WO2015070470A1 (en) | Complex carbohydrate formulation for fodder, fodder comprising same, and application | |
| CN105341363A (en) | Novel compound feed additive for livestock | |
| CN102078522A (en) | Chinese medicine composition for treating enterovirus syndrome in chicken | |
| CN114698742A (en) | Piglet feed containing micro-ecological traditional Chinese medicine preparation | |
| CN1328971C (en) | Growth promoter of green natural plant | |
| CN111357885A (en) | Complete feed and premix for promoting body shape and skeleton development of laying chicks and preparation method thereof | |
| CN101715893B (en) | Pure natural piglet immunological enhancement feed additive and application thereof | |
| CN105454712A (en) | Silkie feed composition | |
| CN116549534B (en) | Pharmaceutical composition for promoting growth of egg chicks and regulating intestinal functions | |
| CN106135748A (en) | A kind of fowl Chinese herbal medicine microorganism composite feed additive | |
| CN102754733A (en) | Novel micro-ecologic preparation for pig and preparation method thereof | |
| CN110179005A (en) | Improve the probiotics and measuring method of squab growth performance | |
| CN101595945A (en) | A kind of feed addictive that promotes production, strengthens the animal disease resistant ability | |
| CN101564084A (en) | Decayed tooth preventing feed additive for improving animal immunizing power | |
| CN111264460A (en) | Selenium-rich laying hen breeding method | |
| CN111149919A (en) | Glycerol butyrate compound for poultry as well as preparation method and application thereof | |
| CN110755604A (en) | Pharmaceutical composition for preventing and treating poultry adenofibromyositis and application thereof | |
| CN1298651A (en) | Concentrated feed for domestic fowls to lay health-care eggs without residual agricultural chemical | |
| CN110025774B (en) | Ointment for preventing and treating newborn piglet diarrhea and production method thereof | |
| CN107594169A (en) | A kind of anti diar rhea pre-mixing agent for reducing Jejunum of Piglets campylobacter and preparation method and application | |
| CN1032897A (en) | Have cure the disease, the novel fodder of immunity, many effects such as fatten | |
| CN113974010A (en) | Feed additive for weaning of bred animals and use method | |
| Maina et al. | Effects of Supplementing Different Levels of Stinging Nettle Leaf Meal on the Growth Performance of Starter Broilers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |